Clinical Trials Sponsored by David Mutimer, Birmingham

Total 83 results

Arrow Therapeutics
DDS, Dundee; David Mutimer, Birmingham; Ed Gane, ACS New Zealand

Terminated

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (CP104)

Chronic Hepatitis C

New Zealand, United Kingdom
Sir Mortimer B. Davis - Jewish General Hospital

Not yet recruiting

Neuromuscular Electrical Stimulation for Children With Dysphagia

Dysphagia
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Novel Robotic Prostatectomy Technique for Early Urinary Continence (TRS-RALP)

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Not yet recruiting

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD (TELO - DMRD)

Multiple Myeloma
Sir Mortimer B. Davis - Jewish General Hospital

Not yet recruiting

Niraparib in High-grade Endometrial Cancer Trial (NIREC)

Endometrial Cancer | Uterine Neoplasm | Serous Adenocarcinoma
Sir Mortimer B. Davis - Jewish General Hospital

Not yet recruiting

The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Active, not recruiting

The MUFFIN-PTS Trial (MUFFIN-PTS)

Post-Thrombotic Syndrome

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

68Ga-PSMA PET/CT in Prostate Cancer

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Urinary Bladder, Overactive | Parkinson Disease

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

Effect of Fructose on Colonic Microflora (MEF)

Healthy

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Unknown

Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression

Major Depression

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Aggressive Smoking Cessation Trial (ASAP) (ASAP)

Acute Coronary Syndrome

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

No Surgery Trial / Two Dose-escalation Strategies (Morpheus)

Stage II Rectal Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors

Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy

Prostate Cancer | Urinary Problems

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Enrolling by invitation

Fluorocholine PET/CT Basket Trial

Fluorocholine PET/CT

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

SUV on PSMA PET/CT in Non-Prostate Tumors

Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Withdrawn

Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women (HyPreC)

COVID-19 | Pregnant Women | SARS-CoV-2 | Hydroxychloroquine
Sir Mortimer B. Davis - Jewish General Hospital

Unknown

Routine Or Selective Stress Testing After Revascularization: ROSSTAR Trial RCT Outline (ROSSTAR)

Coronary Artery Disease | Coronary Heart Disease
Sir Mortimer B. Davis - Jewish General Hospital

Unknown

Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism (ELOPE)

Pulmonary Embolism

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Hypotension Prediction Index in Postoperative Surgical Patients (HPI-PACU)

Surgery

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Montreal Immune-Related Adverse Events (MIRAE) Study (MIRAE)

Autoimmune Diseases | Cancer | Immune System Disorder | Inflammatory Reaction

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life. (Pathos)

Patient Preference

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Management of Castration-Resistant Prostate Cancer With Oligometastases (PCS IX)

Castration-resistant Prostate Cancer Patients With Oligometastases

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Enrolling by invitation

Prostate Cancer Patient Management With 18F-DCFPyL PET/CT

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

Exploring the Effect of Video Interventions on Intentions for Continued COVID-19 Vaccination

COVID-19 | Vaccine Refusal

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Active, not recruiting

Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital

Completed

Correlation Between SUV on 18F-Fluorocholine PET/CT and Gleason Score in Prostate Cancer

Prostate Cancer

Canada
Sir Mortimer B. Davis - Jewish General Hospital
Abbott

Recruiting

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

Adenocarcinoma of the Prostate

Canada
Sir Mortimer B. Davis - Jewish General Hospital
Sanofi

Completed

A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer

Operable T2-3N+M0 Rectal Cancer (Stage III)

Canada
Zeev Rosberger

Completed

Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention

Vaccine Refusal

Canada
McGill University
Sir Mortimer B. Davis - Jewish General Hospital

Completed

Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial

Smoking Cessation

Canada
Khashayar Esfahani

Recruiting

Tofacitinib for the Treatment of Refractory Immune-related Colitis From Checkpoint Inhibitor Therapy- TRICK Study

Immune-Mediated Colitis

Canada
Sir Mortimer B. Davis - Jewish General Hospital
Icad, Inc.

Recruiting

Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy (Whistle)

Rectal Cancer | Inoperable Disease | Comorbidities and Coexisting Conditions | Brachytherapy

Canada
Sir Mortimer B. Davis - Jewish General Hospital
Novartis Pharmaceuticals

Withdrawn

Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries

Hypertension | Diabetes

Canada
Sir Mortimer B. Davis - Jewish General Hospital
Cancer Research Network

Terminated

Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms

Lower Urinary Tract Symptoms | Bladder Carcinoma | BCG

Canada
Sarit Assouline
Novartis

Recruiting

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-Positive

Canada
Sir Mortimer B. Davis - Jewish General Hospital
Danone Institute International

Completed

Effects of Lactose on Fecal Microflora (ELM)

Lactose Intolerance

Canada
Sir Mortimer B. Davis - Jewish General Hospital
Avario Healthcare Inc.

Terminated

Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis

Breast Cancer | Head and Neck Cancer

Canada
Dr. Tamim Niazi
AstraZeneca

Active, not recruiting

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Prostate Cancer

Canada
University of Colorado, Denver
Sir Mortimer B. Davis - Jewish General Hospital

Completed

The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer

Prostate Cancer

United States
Sir Mortimer B. Davis - Jewish General Hospital
Merck Frosst Canada Ltd.

Terminated

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

Pre-diabetes | Pre-hypertension

Canada

Clinical Trials Sponsored by David Mutimer, Birmingham

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations